AML typical mutations (CEBPA, FLT3, NPM1) identify a high-risk chronic myelomonocytic leukemia independent of CPSS molecular
Key PointsInfrequent in CMML, AML-like mutations (CEBPA, FLT3, or NPM1) detect poor-prognosis CMML.
Related Articles
Blood Podcast | Blood | American Society of Hematology
Blood Podcast | Blood | American Society of Hematology Blood Podcast The editors of Blood are pleased to introduce a podcast series, published weekly…
Impact of Non-Alcoholic Fatty Liver Disease (NAFLD) on Platelet Count
Abstract. BACKGROUND: It is well established that alcohol use and chronic viral hepatitis negatively affect the peripheral platelet count. However, less is
Lymphopenia predicts poor outcomes in newly diagnosed multiple myeloma
Key PointsLymphopenia at diagnosis and follow-up predicts inferior OS in patients with MM.ALC is a readily available biomarker and predictor of outcomes in
VJOncology – The video journal of oncology
The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the…
Tislelizumab Combo Shows Promise in HER2-Negative Gastric/GEJ Cancer
Tislelizumab combined with irinotecan, paclitaxel, oxaliplatin, and 5-FU/leucovorin proved effective with manageable safety as frontline therapy for advanced HER2-negative, mismatch repair–proficient gastric and GEJ adenocarcinoma…
First-Line FOLFIRINOX Fails to Improve OS vs First-Line NALIRIFOX in Metastatic PDAC
The median OS with frontline FOLFIRINOX was numerically lower than that seen with frontline NALIRIFOX in patients with metastatic PDAC.
Dose Reductions of Liposomal Irinotecan, Oxaliplatin Are Not Associated With Worsened OS in Metastatic PDAC
NAPOLI 3 post hoc findings show dose reductions of liposomal irinotecan or oxaliplatin did not worsen OS in pancreatic ductal adenocarcinoma.
Experts Share New Insights, Key Updates During Final Plenary Session of the 2024 ACLC – ILCN.org (ILCN/WCLC)
Takeaways included updates from the CheckMate 816 study, advances in technology, the role of metabolites and mobile CT screening in predicting cancer risk, and the…
City of Hope: Making a profound difference as we pursue cancer cures at the speed of life – The Cancer Letter
I am pleased to begin a new series from City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the…
BPDCN: state of the art
Abstract. The emergence of blastic plasmacytoid dendritic cell neoplasm (BPDCN) as its own distinct entity within the pantheon of hematologic malignancies
